Frankfurt - Delayed Quote EUR
Thermo Fisher Scientific Inc. (TN8.F)
378.00
+7.35
+(1.98%)
As of 9:37:25 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 27 | 27 |
| Avg. Estimate | 10.7B | 10.85B | 43.71B | 46.45B |
| Low Estimate | 10.49B | 10.71B | 43.36B | 45.33B |
| High Estimate | 10.95B | 11B | 44.01B | 48.04B |
| Year Ago Sales | 10.54B | 10.6B | 42.88B | 43.71B |
| Sales Growth (year/est) | 1.50% | 2.35% | 1.94% | 6.27% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TN8.F | -- | -- | -- | -- |
| S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 4/24/2025 |
| Maintains | UBS: Buy to Buy | 4/24/2025 |
| Maintains | Stifel: Buy to Buy | 4/24/2025 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 4/24/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 4/24/2025 |
| Maintains | Baird: Outperform to Outperform | 4/24/2025 |